Vera Therapeutics

Our Company

Our mission is to change the standard of care for patients with immunologic diseases. We are developing multiple novel biologic molecules toward this end.

Our lead clinical candidate is atacicept:

  • A fusion protein that acts as an inhibitor of B cells and plasma cells, the cells that can produce disease causing antibodies.
  • In a Ph2b clinical trial, the ORIGIN study, for IgA nephropathy (IgAN), an autoimmune disease that leads to kidney failure – for which no disease-modifying treatment is currently available.
  • Initiating a Ph 3 clinical trial in Lupus Nephritis (LN), a severe kidney manifestation of systemic lupus erythematosus (SLE).
  • Target profile: self-administered subcutaneously once per week.

We are also advancing MAU868:

  • A monoclonal antibody that neutralizes infection by blocking BKV virion binding to host cells.
  • In a Ph2 clinical trial for treatment of BK viremia in kidney transplant patients.
  • No BK-specific treatment currently available.
  • Target profile: monthly IV administration.

Our Team

Marshall Fordyce, MD

CEO and Founder

Celia Lin, MD

Chief Medical Officer

Lauren Frenz, MBA

Chief Business Officer

Joanne Curley, PhD

Chief Development Officer

Sean Grant, MBA

Chief Financial Officer

Tom Doan

SVP, Development Operations

Joseph Young, MBA

Chief Accounting Officer

Julien E. Capers, JD

VP, Head of Legal

Kelly Rauber

VP, Head of Human Resources

Neeraj Pakala, PhD, MBA

SVP, Product Development and Manufacturing

Board of Directors

Michael M. Morrissey, PhD

President and CEO
Exelixis

Andrew Cheng, MD, PhD

President and CEO
Akero Therapeutics

Beth Seidenberg, MD

General Partner
Kleiner Perkins

Maha Katabi, PhD, CFA

General Partner
Sofinnova Investments

Patrick Enright, MBA

Managing Director
Longitude Capital

Scott Morrison

Former Partner and US Life Sciences Leader
EY

Marshall Fordyce, MD

President and CEO
Vera Therapeutics

Kimball Hall

President and COO
Abzena
Top